Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Exclusive Breastfeeding and the Effect on Postpartum Multiple Sclerosis Relapses.

Hellwig K, Rockhoff M, Herbstritt S, Borisow N, Haghikia A, Elias-Hamp B, Menck S, Gold R, Langer-Gould A.

JAMA Neurol. 2015 Oct;72(10):1132-8. doi: 10.1001/jamaneurol.2015.1806. Erratum in: JAMA Neurol. 2016 Apr;73(4):481.

PMID:
26322399
2.

Natalizumab use during the third trimester of pregnancy.

Haghikia A, Langer-Gould A, Rellensmann G, Schneider H, Tenenbaum T, Elias-Hamp B, Menck S, Zimmermann J, Herbstritt S, Marziniak M, Kümpfel T, Meinl I, Plavina T, Gold R, Hellwig K.

JAMA Neurol. 2014 Jul 1;71(7):891-5. doi: 10.1001/jamaneurol.2014.209. Review.

PMID:
24821217
3.

Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis.

Radue EW, O'Connor P, Polman CH, Hohlfeld R, Calabresi P, Selmaj K, Mueller-Lenke N, Agoropoulou C, Holdbrook F, de Vera A, Zhang-Auberson L, Francis G, Burtin P, Kappos L; FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) Study Group.

Arch Neurol. 2012 Oct;69(10):1259-69.

PMID:
22751847
4.

Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.

Devonshire V, Havrdova E, Radue EW, O'Connor P, Zhang-Auberson L, Agoropoulou C, Häring DA, Francis G, Kappos L; FREEDOMS study group.

Lancet Neurol. 2012 May;11(5):420-8. doi: 10.1016/S1474-4422(12)70056-X. Epub 2012 Apr 10. Erratum in: Lancet Neurol. 2012 Aug;11(8):658.

PMID:
22494956
5.

Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.

Radue EW, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Rudick RA, Lublin FD, Weinstock-Guttman B, Wynn DR, Fisher E, Papadopoulou A, Lynn F, Panzara MA, Sandrock AW; SENTINEL Investigators.

J Neurol Sci. 2010 May 15;292(1-2):28-35. doi: 10.1016/j.jns.2010.02.012. Epub 2010 Mar 16.

PMID:
20236661
6.

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P; FREEDOMS Study Group.

N Engl J Med. 2010 Feb 4;362(5):387-401. doi: 10.1056/NEJMoa0909494. Epub 2010 Jan 20.

7.

Monocyte/macrophage differentiation in dermatomyositis and polymyositis.

Rostasy KM, Piepkorn M, Goebel HH, Menck S, Hanefeld F, Schulz-Schaeffer WJ.

Muscle Nerve. 2004 Aug;30(2):225-30.

PMID:
15266639
8.

Iatrogenic epidural spinal abscess.

Bollensen E, Menck S, Buzanoski J, Prange HW.

Clin Investig. 1993 Oct;71(10):780-6.

PMID:
8305833
9.

Passage of cefotaxime and ceftriaxone into cerebrospinal fluid of patients with uninflamed meninges.

Nau R, Prange HW, Muth P, Mahr G, Menck S, Kolenda H, Sörgel F.

Antimicrob Agents Chemother. 1993 Jul;37(7):1518-24.

10.
11.

Penetration of rifampicin into the cerebrospinal fluid of adults with uninflamed meninges.

Nau R, Prange HW, Menck S, Kolenda H, Visser K, Seydel JK.

J Antimicrob Chemother. 1992 Jun;29(6):719-24.

PMID:
1506352

Supplemental Content

Loading ...
Support Center